Your shopping cart is empty
Subscriber login
REGISTER FOR FREE EZINES
Advanced Search
- Please Select -
Regulation
Business Development
Drug Manufacturing
Device Manufacturing
Quality Management
Home
Books
Conferences
Newsletters
Training
White Papers
Advertising
Contact Us
About Us
Check out our free and informative ezines and sign up now
Sign Up
Home
>
Newsletters
>
FDAnews Drug Daily Bulletin
> Charles River Calls Off WuXi PharmaTech Buy
FDAnews Drug Daily Bulletin
Aug. 2, 2010
| Vol. 7 No. 149
Charles River Calls Off WuXi PharmaTech Buy
Charles River Laboratories International, a U.S. medical research equipment and services company, said it is canceling a $1.6 billion acquisition of WuXi PharmaTech after shareholder objections.
The Seattle Times
Register Now
Print This Page
Email This Article
RSS
Archives
Related Articles
Sanofi Pitched $71 Offer to Genzyme
Mylan Completes $550 Million Acquisition of Bioniche Pharma
Lonza Signs Production Deal With Glaxo
Onyx Pharma Gets Japanese Drug Development Deal